Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is positioned for strong growth due to increasing expectations for Giapreza, which is addressing a significant unmet need in the management of septic shock, supported by improved access and potential updates to treatment guidelines. The commercial momentum is further highlighted by Xacduro's rapid sales growth, with projected revenues reaching $21.1 million in 2024 and an impressive run rate of $95.3 million by 3Q25. Additionally, the company benefits from durable patent protection, which enhances its revenue outlook and reinforces the positive sentiment around its expanding healthcare asset portfolio.

Bears say

Innoviva Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to high mortality rates associated with infections like MRSA, which complicate the market potential for its healthcare assets. The company is also at risk of failing to successfully commercialize its marketed products and launch new drugs, such as ZEVTERA and zoliflodacin, amidst a landscape of rising antibiotic resistance that impacts treatment efficacy. Furthermore, there are concerns regarding declining royalty revenues from respiratory products due to potential generic erosion and broader macroeconomic risks that could adversely affect the company's financial stability.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.